Late and Very Late Thrombosis of Drug-Eluting Stents. Evolving Concepts and Perspectives

Journal of the American College of Cardiology

Volumn 50, Issue 2, 2007, Pages 119-127

  Jaffe, Ronen ^a   Strauss, Bradley H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTOZAL; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; THIENOPYRIDINE; UNCLASSIFIED DRUG;

BLOOD CLOT LYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY STENT; DRUG ELUTING STENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MORTALITY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK ASSESSMENT; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

CORONARY DISEASE; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; HUMANS; INCIDENCE; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RISK FACTORS; STENTS;

EID: 34347211024     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.04.031     Document Type: Review

References (71)

1. Bavry A.A., Kumbhani D.J., Helton T., Borek P., Mood G., and Bhatt D. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
2. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
3. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
4. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
5. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
6. Cutlip D.E., Baim D.S., Ho K.K., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001) 1967-1971
7. Ong A.T., Hoye A., Aoki J., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45 (2005) 947-953
8. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
9. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
10. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
11. Wenaweser P., Rey C., Eberli F.R., et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 26 (2005) 1180-1187
12. Farb A., Burke A.P., Kolodgie F.D., and Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
13. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
14. Colombo A., Moses J.W., Morice M.C., et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 109 (2004) 1244-1249
15. Ge L., Airoldi F., Iakovou I., et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol 46 (2005) 613-620
16. Hoye A., Iakovou I., Ge L., et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol 47 (2006) 1949-1958
17. Williams D., Abbott J., and Kip K. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents. Report of the DEScover Registry. Circulation 114 (2006) 2154-2162
18. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
19. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
20. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455
21. Luscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
22. Kotani J., Awata M., Nanto S., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
23. Bavry A.A., Kumbhani D.J., Helton T.J., and Bhatt D.L. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?. A meta-analysis. J Am Coll Cardiol 45 (2005) 941-946
24. Morice M.C., Colombo A., Meier B., et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904
25. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 (2005) 819-825
26. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
27. Ellis S.G., Colombo A., Grube E., et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 49 (2007) 1043-1051
28. Urban P., Gershlick A.H., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
29. Valgimigli M., Percoco G., Malagutti P., et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
30. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
31. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
32. Fujii K., Carlier S.G., Mintz G.S., et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 45 (2005) 995-998
33. Biondi-Zoccai G.G., Agostoni P., Sangiorgi G.M., et al. Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. Eur Heart J 27 (2006) 540-546
34. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
35. Vermeersch P., Agostoni P., Verheye S., et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial. J Am Coll Cardiol 48 (2006) 2423-2431
36. Iakovou I., Ge L., and Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol 46 (2005) 1446-1455
37. Ong A.T., McFadden E.P., Regar E., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
38. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
39. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
40. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45 (2005) 1157-1164
41. Wang T.H., Bhatt D.L., and Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27 (2006) 647-654
42. Wenaweser P., Dorffler-Melly J., Imboden K., et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45 (2005) 1748-1752
43. Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 46 (2005) 1827-1832
44. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., and Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 (2007) 657-666
45. Macchi L., Christiaens L., Brabant S., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
46. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
47. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
48. Mukherjee D., Kline-Rogers E., Fang J., Munir K., and Eagle K.A. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 91 (2005) 23-26
49. Finn A.V., Kolodgie F.D., Harnek J., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
50. Kereiakes D.J., Wang H., Popma J.J., et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol 48 (2006) 21-31
51. Hofma S.H., van der Giessen W.J., van Dalen B.M., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
52. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
53. Uren N.G., Schwarzacher S.P., Metz J.A., et al. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur Heart J 23 (2002) 124-132
54. Mintz G.S., and Weissman N.J. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol 48 (2006) 421-429
55. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
56. Serruys P.W., Degertekin M., Tanabe K., et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation 106 (2002) 798-803
57. Ako J., Morino Y., Honda Y., et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 46 (2005) 1002-1005
58. Tanabe K., Serruys P.W., Degertekin M., et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation 111 (2005) 900-905
59. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
60. Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol 47 (2006) 2112-2115
61. Nebeker J.R., Virmani R., Bennett C.L., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
62. Colombo A., Hall P., Nakamura S., et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 91 (1995) 1676-1688
63. Leon M.B., Baim D.S., Popma J.J., et al., Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339 (1998) 1665-1671
64. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996) 1084-1089
65. Bertrand M.E., Legrand V., Boland J., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin And Ticlopidine (FANTASTIC) study. Circulation 98 (1998) 1597-1603
66. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
67. O'Donoghue M., and Wiviott S. Clopidogrel response variability and future therapies. Clopidogrel: does one size fit all?. Circulation 114 (2006) e600-e606
68. Lee S.W., Park S.W., Hong M.K., et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 46 (2005) 1833-1837
69. Serruys P.W. Fourth annual American College of Cardiology international lecture: a journey in the interventional field. J Am Coll Cardiol 47 (2006) 1754-1768
70. Food and Drug Administration. Circulatory System Devices Advisory Panel transcript for December 8, 2006, meeting. Available at: http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4253t2.rtf. Accessed January 25, 2007.
71. Harrington R.A., and Califf R.M. Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?. J Am Coll Cardiol 48 (2006) 2592-2595